Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

Koeberle, Dieter; Saletti, Piercarlo; Borner, Markus; Gerber, Daniela; Dietrich, Daniel; Caspar, Clemens B.; Mingrone, Walter; Beretta, Kurt; Strasser, Florian; Ruhstaller, Thomas; Mora, O; Herrmann, Richard

doi:10.1200/jco.2008.16.5704

Cited by 68 publications

(61 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditionally, 5-fluorouracil-based chemotherapy regimen has been used as an adjuvant therapy for biliary tract malignancies including GB cancer [6,9,20,21]. Recently, gemcitabine-, capecitabine, or S-1-based regimens have been tried, and several studies have demonstrated somewhat promising results from GB cancer [22][23][24][25][26]. However, few comparative analyses of treatments between detailed TNM stages of GB cancer have been reported.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant chemoradiation therapy in gallbladder cancer

Cho

Kim

Park

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: Gallbladder cancer is a relatively uncommon gastrointestinal malgnancy. Indications for adjuvant chemoradiation therapy after surgical resection have not yet been determined. We aimed this study to elucidate the effectiveness of adjuvant chemoradiation therapy according to TNM stage for gallbladder cancer. Methods: Between March 2001 and March 2009, 100 patients with gallbladder cancer underwent surgical resection. We divided the patients according to TNM stage, and subdivided further according to whether adjuvant chemoradiation therapy was added or not. The clinicopathologic factors, recurrence and survival were retrospectively analyzed. Results: Patients with gallbladder cancer at T2N0M0, T2N1M0, T3N0M0, and T3N1M0 stages were enrolled in this study. Among the four stages, the two lymph node-negative stages (T2N0M0 and T3N0M0) did not show any gain in survival by adding adjuvant chemoradiation therapy. Conversely, the remaining lymph node-positive stages (T2N1M0 and T3N1M0) showed gain in disease-free survival, and the lymph node-positive T2 stage (T2N1M0) showed gain in disease-specific survival. In patients with lymph node-positive T2/T3 GB cancers, adjuvant chemoradiation therapy was an independent prognostic factor for survival. Conclusions: Adjuvant chemoradiation therapy is recommended for lymph node-positive T2/T3 gallbladder cancer following surgical resection.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant chemoradiation therapy in gallbladder cancer

Cho

Kim

Park

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…However, no standard chemotherapy regimen for advanced BTC has been established. Several phase II trials with new chemotherapeutic agents, such as gemcitabine (6)(7)(8)(9)(10), capecitabine (11), oxaliplatin (12), or S-1 (13,14) have demonstrated tumor response in ~15-35% of patients treated with single agents, and in 20-40% of patients treated with their combinations (15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Among them, gemcitabine has shown promising activity against advanced BTC, and has been commonly used for patients with unresectable or recurrent BTC in Japan.…”

Section: Introductionmentioning

confidence: 99%

Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma

Nakamura

Kohya²,

Kai³

et al. 2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. Gemcitabine is a commonly used chemotherapeutic agent for advanced biliary tract carcinoma (BTC), although its efficacy is insufficient. Therefore, it is essential to establish new diagnostic methods, which can predict responders before the treatment. The aim of this study is to identify the most reliable chemoresistance marker to gemcitabine in BTC among the 4 molecules (hENT1, dCK, RRM1 and RRM2) involved in gemcitabine metabolism. The expression of 4 molecules were investigated in 5 BTC cell lines, and correlated with gemcitabine sensitivity. RRM1 protein was also assessed by quantitative double-fluorescence immunohistochemistry (qDFIHC) in 10 patients with unresectable or recurrent BTC who received gemcitabine-based chemotherapy. RRM1 and RRM2 protein strongly correlated with the IC 50 value for gemcitabine in BTC cell lines (R=0.935, 0.771, respectively). In addition, patients with low RRM1 were significantly more sensitive to gemcitabine (p=0.033), and their survival was significantly better than patients with high RRM1 (p=0.001).In conclusion, RRM1 particularly in protein level is a reliable marker for gemcitabine resistance in BTC. Furthermore, qDFIHC is a useful method for the assessment of RRM1 protein, in order to design a tailor-made chemotherapeutic regimen for BTC patients.

show abstract

“…Based on these results, the combination of gemcitabine and cisplatin is considered to be the standard of care for first-line chemotherapy for patients with advanced or metastatic biliary tract cancers. Examples of other gemcitabine-based or fluoropyrimidine-based (fluorouracil or capecitabine) regimens with demonstrated activity in phase II trials include gemcitabine and cisplatin or oxaliplatin [165][166][167][168][169][170][171][172][173] ; gemcitabine and fluoropyrimidine [174][175][176][177][178][179] ; and fluoropyrimidine and oxaliplatin or cisplatin. [180][181][182][183] Triple-drug chemotherapy regimens also have been shown to be effective in patients with advanced biliary tract cancers, albeit in a very small number of patients.…”

Section: Chemotherapy and Chemoradiation For Advanced Biliary Tract Cmentioning

confidence: 99%

Hepatobiliary Cancers, Version 2.2014

Benson¹,

D’Angelica²,

Abrams³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research

Abstract: Chemotherapy with GemCap is well tolerated and effective and leads to a high CBR rate. Patient-reported outcomes are useful for evaluating the effects of palliative chemotherapy in patients with biliary tract cancer.

Cited by 68 publications

References 37 publications

Adjuvant chemoradiation therapy in gallbladder cancer

Adjuvant chemoradiation therapy in gallbladder cancer

Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma

Hepatobiliary Cancers, Version 2.2014

Contact Info

Product

Resources

About